The Lancet Oncology in conversation with
by The Lancet Group
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 5 chart positions in 5 markets.
By chart position
- 🇮🇹IT · Medicine#17100K to 300K
- 🇰🇷KR · Medicine#6010K to 30K
- 🇯🇵JP · Medicine#1261K to 10K
- 🇮🇱IL · Medicine#933K to 10K
- 🇫🇮FI · Medicine#113500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
57K to 177K🎙 ~2x weekly·75 episodes·Last published 2mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
115K to 353K🇮🇹85%🇰🇷8%🇯🇵3%+2 more - Active Followers
Loyal subscribers who consistently listen
34K to 106K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 12 epsHosts
Recent guests
Recent episodes
Hans Merks on European guidelines for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma
Jun 29, 2026
12m 39s
Hedvig Hricak and Zachary Ward on Cancer workforce—a global crisis: a Lancet Oncology Commission
May 31, 2026
23m 36s
Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer
Apr 27, 2026
13m 01s
James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
Mar 30, 2026
10m 55s
Ali Landman on the European Congress of Radiology 2026
Mar 17, 2026
15m 00s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/29/26 | imagingosteosarcoma+4 | Hans Merks | The Lancet GroupThe Lancet+1 | — | osteosarcomaEwing sarcoma+4 | — | 12m 39s | ||
| 5/31/26 | cancer workforceglobal health crisis+3 | Dr Hedvig HricakDr Zachary Ward | Memorial Sloan Kettering Cancer CenterHarvard TH Chan School of Public Health+2 | New York, NY, USABoston, MA, USA | cancer workforceglobal crisis+3 | — | 23m 36s | ||
| 4/27/26 | quality of lifemetastatic prostate cancer+3 | Professor Fred Saad | Department of Surgery/Urology, University of MontrealThe Lancet Oncology+1 | Montreal, QC, Canada | metastatic hormone-sensitive prostate cancerquality of life+3 | — | 13m 01s | ||
| 3/30/26 | prostate cancertheranostics+4 | James Nagarajah | [177Lu]-PSMA-617-PSMA-617The Lancet Oncology+1 | — | prostate cancerBULLSEYE+4 | — | 10m 55s | ||
| 3/17/26 | oncological imagingradiology+3 | Ali Landman | The Lancet Medical Imaging & Theranostics | Vienna | oncological imagingradiology+3 | — | 15m 00s | ||
| 3/9/26 | breast cancerepidemiological trends+4 | Kayleigh Bhangdia | GBD | 204 countries | breast cancerGBD study+5 | — | 18m 23s | ||
| 2/2/26 | qualitative researchoncology+3 | Dr Dylan GraetzDr Erica Kaye | St Jude Children’s Research HospitalThe Power of Words: Evaluating the Role of Qualitative Methods in Cancer Research | — | qualitative researchoncology+3 | — | 42m 58s | ||
| 12/29/25 | cancer mortalityoccupation+3 | Dr Jesse PlascakDr Marissa Baker | The Ohio State UniversityUniversity of Washington School of Public Health | — | cancermortality rates+6 | — | 23m 47s | ||
| 11/25/25 | digital healthartificial intelligence+3 | Dr Andre PfobProf Peter Dubsky | Heidelberg University HospitalUniversity of Lucerne+1 | — | digital healthartificial intelligence+3 | — | 26m 34s | ||
| 11/2/25 | cancer carehuman dimensions+3 | Dr Gary Rodin | Lancet OncologyThe Lancet Group | — | cancerhuman crisis+4 | — | 10m 46s | ||
| 10/27/25 | clinical trialsbrain metastases+3 | Matthias Preusser | patritumab deruxtecanMedical University of Vienna+1 | Vienna, Austria | TUXEDO-3patritumab deruxtecan+5 | — | 17m 10s | ||
| 9/29/25 | bladder cancerneoadjuvant therapy+4 | Dr Andrea Necchi | Vita-Salute San Raffaele UniversitySan Raffaele Hospital+1 | — | muscle-invasive bladder cancerTAR-200+4 | — | 12m 15s |
Showing 12 of 12
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Similar Audience Demographics
Podcasts that attract a similar listener profile
Chart history for The Lancet Oncology in conversation with
Peaked at #17 in Italy, currently #17 in Italy.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| Italy | — | #17 | #17 | — |
| South Korea | — | #60 | #60 | — |
| IL | — | #93 | #93 | — |
| Finland | — | #113 | #113 | — |
| Japan | — | #126 | #126 | — |
| Italy | — | #128 | #128 | — |
Chart Positions
6 placements across 5 markets.
Chart Positions
6 placements across 5 markets.